Patent · US Active

Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders

US9265842B2 · kind B2 · utility

0Cited by
3References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 13, 2011
Grant dateFeb 23, 2016
Priority date
Expiry dateOct 13, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/002
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Recombinant cells and methods are provided that relate to the use of isolated, engineered recombinant cells to directly or indirectly treat diseases or disorders in a mammalian host such as endocrine, gastrointestinal or autoimmune disorders. A recombinant cell is provided that comprises a signal sequence and a promoter, wherein: the signal sequence is capable of regulating signal-dependent expression of a target nucleic acid in a host or is capable of regulating signal-dependent expression of a target nucleic acid in response to an environmental stimulus, the cell is derived from an enteric or a commensal bacterium, and the target nucleic acid encodes a mammalian factor that promotes normal functioning of a physiological process in the host or is effective in preventing onset, establishment, or spread of a non-infectious disease in the host. The recombinant cell is administered to the host to treat the disease or disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.